-
Future Microbiology 2015Live attenuated oral polio vaccine (OPV) and inactivated polio vaccine (IPV) are the tools being used to achieve eradication of wild polio virus. Because OPV can rarely... (Review)
Review
Live attenuated oral polio vaccine (OPV) and inactivated polio vaccine (IPV) are the tools being used to achieve eradication of wild polio virus. Because OPV can rarely cause paralysis and generate revertant polio strains, IPV will have to replace OPV after eradication of wild polio virus is certified to sustain eradication of all polioviruses. However, uncertainties remain related to IPV's ability to induce intestinal immunity in populations where fecal-oral transmission is predominant. Although substantial effectiveness and safety data exist on the use and delivery of OPV and IPV, several new research initiatives are currently underway to fill specific knowledge gaps to inform future vaccination policies that would assure polio is eradicated and eradication is maintained.
Topics: History, 20th Century; History, 21st Century; Humans; Poliomyelitis; Poliovirus Vaccines; Vaccination; Vaccines, Attenuated; Vaccines, Inactivated
PubMed: 25824845
DOI: 10.2217/fmb.15.19 -
Cell Host & Microbe May 2020The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in gut-associated tissues, eliciting mucosa and systemic immunity. OPV protects from...
The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in gut-associated tissues, eliciting mucosa and systemic immunity. OPV protects from disease and limits poliovirus spread. Accordingly, vaccination with OPV is the primary strategy used to end the circulation of all polioviruses. However, the ability of OPV to regain replication fitness and establish new epidemics represents a significant risk of polio re-emergence should immunization cease. Here, we report the development of a poliovirus type 2 vaccine strain (nOPV2) that is genetically more stable and less likely to regain virulence than the original Sabin2 strain. We introduced modifications within at the 5' untranslated region of the Sabin2 genome to stabilize attenuation determinants, 2C coding region to prevent recombination, and 3D polymerase to limit viral adaptability. Prior work established that nOPV2 is immunogenic in preclinical and clinical studies, and thus may enable complete poliovirus eradication.
Topics: Adult; Animals; Chlorocebus aethiops; Disease Models, Animal; Female; Genetic Engineering; HeLa Cells; Humans; Immunogenicity, Vaccine; Male; Mice; Poliomyelitis; Poliovirus; Poliovirus Vaccine, Oral; RNA, Viral; RNA-Dependent RNA Polymerase; Recombination, Genetic; Vaccination; Vaccines, Attenuated; Vero Cells; Virulence
PubMed: 32330425
DOI: 10.1016/j.chom.2020.04.003 -
Methods in Molecular Biology (Clifton,... 2016Poliomyelitis is caused by poliovirus, which is a positive strand non-enveloped virus that occurs in three distinct serotypes (1, 2, and 3). Infection is mainly by the...
Poliomyelitis is caused by poliovirus, which is a positive strand non-enveloped virus that occurs in three distinct serotypes (1, 2, and 3). Infection is mainly by the fecal-oral route and can be confined to the gut by antibodies induced either by vaccine, previous infection or maternally acquired. Vaccines include the live attenuated strains developed by Sabin and the inactivated vaccines developed by Salk; the live attenuated vaccine (Oral Polio Vaccine or OPV) has been the main tool in the Global Program of Polio eradication of the World Health Organisation. Wild type 2 virus has not caused a case since 1999 and type 3 since 2012 and eradication seems near. However most infections are entirely silent so that sophisticated environmental surveillance may be needed to ensure that the virus has been eradicated, and the live vaccine can sometimes revert to virulent circulating forms under conditions that are not wholly understood. Cessation of vaccination is therefore an increasingly important issue and inactivated polio vaccine (IPV) is playing a larger part in the end game.
Topics: Global Health; Humans; Poliomyelitis; Poliovirus; Poliovirus Vaccine, Inactivated; Poliovirus Vaccine, Oral; Vaccination; Vaccines, Attenuated
PubMed: 26983727
DOI: 10.1007/978-1-4939-3292-4_1 -
The Journal of Infectious Diseases Nov 2014The attenuated oral poliovirus vaccine (OPV) has many properties favoring its use in polio eradication: ease of administration, efficient induction of intestinal... (Review)
Review
The attenuated oral poliovirus vaccine (OPV) has many properties favoring its use in polio eradication: ease of administration, efficient induction of intestinal immunity, induction of durable humoral immunity, and low cost. Despite these advantages, OPV has the disadvantage of genetic instability, resulting in rare and sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of genetically divergent vaccine-derived polioviruses (VDPVs). Whereas VAPP is an adverse event following exposure to OPV, VDPVs are polioviruses whose genetic properties indicate prolonged replication or transmission. Three categories of VDPVs are recognized: (1) circulating VDPVs (cVDPVs) from outbreaks in settings of low OPV coverage, (2) immunodeficiency-associated VDPVs (iVDPVs) from individuals with primary immunodeficiencies, and (3) ambiguous VDPVs (aVDPVs), which cannot be definitively assigned to either of the first 2 categories. Because most VDPVs are type 2, the World Health Organization's plans call for coordinated worldwide replacement of trivalent OPV with bivalent OPV containing poliovirus types 1 and 3.
Topics: Genotype; Humans; Poliovirus; Poliovirus Vaccine, Oral; Vaccines, Attenuated; Virulence; Virus Shedding
PubMed: 25316847
DOI: 10.1093/infdis/jiu295 -
Best Practice & Research. Clinical... Oct 2021Neonatal immunisation includes vaccination in the first 4 weeks of life (Neonatal period) as well as in high-risk preterm infants in the first few months (until 44 weeks... (Review)
Review
Neonatal immunisation includes vaccination in the first 4 weeks of life (Neonatal period) as well as in high-risk preterm infants in the first few months (until 44 weeks corrected gestational age). Neonates have an immature immune system, which renders them highly susceptible to life-threatening infections. This highlights the importance of vaccination in this vulnerable population; however, at the same time also making it challenging because of their inability to generate a protective immune response. Other challenges include interference from maternal antibodies and excessive skewing towards T Helper Cell Type 2 (Th2) immunity. Despite these challenges, several vaccines have been developed and proven safe and effective at birth. Presently, there are 3 vaccines - Hepatitis B vaccine, Bacillus Calmette-Guerine (BCG) and Oral Polio vaccine (OPV) widely used in neonates, which provides evidence that certain antigen-adjuvant combinations can elicit protective neonatal responses. This review focusses on current vaccinations in neonates, including preterm infants and highlights some novel approaches to enhance neonatal vaccination.
Topics: Humans; Infant; Infant, Newborn; Infant, Premature; Poliovirus Vaccine, Oral; Vaccination
PubMed: 33129673
DOI: 10.1016/j.bpobgyn.2020.09.004 -
The Medical Letter on Drugs and... Oct 2022
Topics: Adult; Haemophilus Vaccines; Humans; Immunization Schedule; Infant; Poliovirus Vaccine, Inactivated; Vaccination
PubMed: 36206162
DOI: No ID Found -
Pediatrics May 2022The majority of children are prescribed antibiotics in the first 2 years of life while vaccine-induced immunity develops. Researchers have suggested a negative...
BACKGROUND
The majority of children are prescribed antibiotics in the first 2 years of life while vaccine-induced immunity develops. Researchers have suggested a negative association of antibiotic use with vaccine-induced immunity in adults, but data are lacking in children.
METHODS
From 2006 to 2016, children aged 6 to 24 months were observed in a cohort study. A retrospective, unplanned secondary analysis of the medical record regarding antibiotic prescriptions and vaccine antibody measurements was undertaken concurrently. Antibody measurements relative to diphtheria-tetanus-acellular pertussis (DTaP), inactivated polio (IPV), Haemophilus influenzae type b (Hib), and pneumococcal conjugate (PCV) vaccines were made.
RESULTS
In total, 560 children were compared (342 with and 218 without antibiotic prescriptions). Vaccine-induced antibody levels to several DTaP and PCV antigens were lower (P < .05) in children given antibiotics. A higher frequency of vaccine-induced antibodies below protective levels in children given antibiotics occurred at 9 and 12 months of age (P < .05). Antibiotic courses over time was negatively associated with vaccine-induced antibody levels. For each antibiotic course the child received, prebooster antibody levels to DTaP antigens were reduced by 5.8%, Hib by 6.8%, IPV by 11.3%, and PCV by 10.4% (all P ≤ .05), and postbooster antibody levels to DTaP antigens were reduced by 18.1%, Hib by 21.3%, IPV by 18.9%, and PCV by 12.2% (all P < .05).
CONCLUSIONS
Antibiotic use in children <2 years of age is associated with lower vaccine-induced antibody levels to several vaccines.
Topics: Anti-Bacterial Agents; Antibodies, Viral; Child; Child, Preschool; Cohort Studies; Diphtheria-Tetanus-acellular Pertussis Vaccines; Haemophilus Vaccines; Humans; Poliovirus Vaccine, Inactivated; Retrospective Studies; Vaccines, Combined
PubMed: 35474546
DOI: 10.1542/peds.2021-052061 -
Vaccine Oct 2016
Topics: Africa; Disease Eradication; Disease Outbreaks; Humans; Poliomyelitis; Poliovirus Vaccines; Public Health
PubMed: 27595897
DOI: 10.1016/j.vaccine.2016.07.042 -
Current Opinion in Infectious Diseases Oct 2020Focusing on the key developments since January 2019, this review aims to inform policymakers and clinical practitioners on the latest on evolving global polio... (Review)
Review
PURPOSE OF REVIEW
Focusing on the key developments since January 2019, this review aims to inform policymakers and clinical practitioners on the latest on evolving global polio epidemiology and scientific advancements to guide strategies for eradication.
RECENT FINDINGS
An upsurge in wild poliovirus type 1 cases in Pakistan and Afghanistan and an expansion of type 2 circulating vaccine-derived poliovirus transmission in multiple countries threaten the remarkable progress made over past several decades by the global eradication program. These challenges have also spurred innovation on multiple fronts, including earlier detection, enhanced environmental surveillance and safer and more affordable vaccine options.
SUMMARY
A concerted effort to adapt program strategies to address context-specific challenges and continued focus on innovations to enhance detection and response capabilities will be the key to achieve and sustain eradication of all types of polioviruses.
Topics: Afghanistan; Disease Eradication; Global Health; Humans; Immunization Programs; Molecular Epidemiology; Pakistan; Poliomyelitis; Poliovirus; Poliovirus Vaccines; RNA, Viral
PubMed: 32773500
DOI: 10.1097/QCO.0000000000000667 -
The Lancet. Global Health Aug 2021The Global Polio Eradication Initiative, launched in 1988 with anticipated completion by 2000, has yet to reach its ultimate goal. The recent surge of polio cases... (Review)
Review
The Global Polio Eradication Initiative, launched in 1988 with anticipated completion by 2000, has yet to reach its ultimate goal. The recent surge of polio cases urgently calls for a reassessment of the programme's current strategy and a new design for the way forward. We propose that the sustainable protection of the world population against paralytic polio cannot be achieved simply by stopping the circulation of poliovirus but must also include maintaining high rates of population immunity indefinitely, which can be created and maintained by implementing global immunisation programmes with improved poliovirus vaccines that create comprehensive immunity without spawning new virulent viruses. The proposed new strategic goal of eradicating the disease rather than the virus would lead to a sustainable eradication of poliomyelitis while simultaneously promoting immunisation against other vaccine-preventable diseases.
Topics: Disease Eradication; Global Health; Humans; Immunization Programs; Poliomyelitis; Poliovirus Vaccines; Program Evaluation
PubMed: 34118192
DOI: 10.1016/S2214-109X(21)00205-9